Hybryte™ awarded innovation passport in the united kingdom

Princeton, n.j., may 10, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that hybryte™ (hypericin) was awarded an "innovation passport" for the treatment of early stage cutaneous t-cell lymphoma (ctcl) in adults under the united kingdom's (uk's) innovative licensing and access pathway (ilap).
SNGX Ratings Summary
SNGX Quant Ranking